Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Approvals ImmunoOncology

Pfizer, CStone Score China's Seventh Immuno-Oncology Approval

Cejemly To Enter Crowded Market

  • Analysis

Executive Summary

Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.

You may also be interested in...



Finance Watch: Financial Market Turmoil Ends Amicus SPAC Deal For Gene Therapy Spinout

Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.

AZ, Junshi Part Ways Amid China IO Commercial Struggle

Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.

Affordable PD-1 From China? CStone Going Global With EQRx Onboard

As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.

Table

View full table

Topics

Related Companies

Tags:
China Approvals ImmunoOncology
Latest Headlines

Jardiance Improves Double-Digit Growth Potential With US Approval In CKD

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo

Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts

See All
UsernamePublicRestriction

Register

SC145628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By